Our purpose is simple: to help researchers (like you) help the world. 

We’re a team of scientists and ultrasonic engineers working together to bring you innovative, high-quality, high-throughput sonication solutions for biological sample preparation. We believe your research is too important to let a simple process like sample prep slow you down.

We’re revolutionizing sample prep for a number of applications, including:

  • DNA shearing for next-generation sequencing
  • Chromatin shearing for ChIP / ChIP-Seq
  • Cell lysis for difficult-to-process samples
  • Protein extraction for mass spectrometry
  • …and more.

Contact us to learn more about our sample prep solutions and/or joining our Research Collaboration Program.



Alicia Wellman, PhD

Scientist II

Dr. Wellman received her Ph.D from North Carolina State University’s Toxicology Department under the mentorship of Dr. Jun Ninomiya-Tsuji where she studied the regulation of the mitogen activated protein kinase kinase kinase (MAP3K) TAK1, and its involvement in reactive oxygen species and intestinal homeostasis. Dr. Wellman furthered her research training by completing a postdoctoral fellowship in the Signal Transduction Laboratory at the National Institute of Environmental Health Sciences (NIEHS) under the direction of Dr. Xiaoling Li where she studied the NAD-dependent protein deacetylase, SIRT1 and its role in regulating intestinal inflammation, physiology and the gut microbiota.

David Allison, PhD

Chief Scientific Officer

Dr. Allison received his PhD from the University of Virginia under the advisement of Dr. Marty Mayo, where he studied the regulation of the proto-oncogene, Nuclear Factor Kappa B. He further developed his research interest in epigenetics during a postdoctoral fellowship at the University of North Carolina Chapel Hill, under the guidance of Dr. Greg Wang, where he became a leading researcher in chromatin biology and high-throughput sequencing workflows.

M. Shamim Hasan Zahid, PhD

Senior Scientist

Dr. Zahid received his PhD from Osaka Prefecture University, Osaka, Japan, where he focused on the discovery of the anti-virulence drugs to combat drug-resistant microbial pathogens. Later, he developed his research interest on cellular microbiology while working as a postdoctoral researcher under the guidance of Dr. Kristy Ainslie at the University of North Carolina at Chapel Hill, where he led research projects on the development and formulation of host-targeted therapy for drug resistant intracellular pathogens.

Ricky McMahon

Chief Business Officer

Ricky received his Master of Business Administration (MBA) degree from the University of North Carolina at Chapel Hill. In addition to his role at Triangle Bio, Ricky is currently a Partner at Bioventure Partners, a life science/medical device investment and advisory firm. Previously, Ricky served as Director of Business Operations at ScienceSeed, a venture capital firm where he helped raise over $20 million for a life science focused investment fund. 

Sunny Kasoji, PhD

Chief Executive Officer | Board of Directors

Dr. Kasoji brings a unique set of engineering and product design/development skills. He has over 6 years of experience developing ultrasonic technologies for biological sample processing and was one of the original scientists that developed the company’s underlying technology. Dr. Kasoji received his PhD under the advisement of Dr. Paul Dayton from the Joint Department of Biomedical Engineering at UNC Chapel Hill/NC State University with a focus on biomedical acoustics for imaging, therapeutics, and sample processing applications.

Zahra Hanafy

Senior Research Asssociate

Zahra received her Master of Science degree majoring in Food Science from North Carolina State University’s Food Science department, and a minor in Biotechnology. Under Dr. Sophia Kathariou’s guidance, she studied natural transformation of antimicrobial resistance markers in Campylobacter spp. She also gained a wide set of skills in isolation, characterization, and identification of several other microbes. Her biotechnology bachelor’s degree and minor has played an important part in the integration of food science, microbiology, and the constant evolving world of cutting-edge technology.

Board and Advisors

Joe McMahon

Co-Founder | Board of Directors

Joe has been working in the life sciences and medical device fields for over 30 years, including 15+ years as the President and CEO of 3 life science companies. Joe is currently Founder and Partner at Bioventure Partners, a life science/medical device investment and advisory firm. Previously, he was the President and CEO of KBI Biopharma, a life science contract development and manufacturing organization. Joe was also previously responsible for the start-up, management and spinout of kSep® Systems from KBI, for which he continued to serve as a board director until 2016, at which time he led the sale of kSep Systems to Sartorius AG.

Paul Dayton, PhD

Co-Founder | Board of Directors

Dr. Dayton has been working in the field of biomedical ultrasonics technologies for more than 20 years. He has over 200 publications in the field, ~10 licensed patents or patent applications, several book chapters, and has presented numerous national and international seminars. He is an expert in cavitation enhancing reagents for imaging, therapeutic, and industrial ultrasonic applications. Dr. Dayton is a co-inventor of Triangle Biotechnology’s underlying technology.

Samantha Pattenden, PhD

Co-Founder | Board of Directors

Dr. Pattenden is a Research Associate Professor and Director of Applied Epigenetic Screening Technologies in the Center for Integrative Chemical Biology and Drug Discovery at Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill. She has over 20 years of experience in the field of epigenetics. Dr. Pattenden is a co-inventor of Triangle Biotechnology’s underlying technology and has spent over 8 years developing the technology.

Bill Janzen

Scientific Advisor

Bill is currently the Vice President of Lead Discovery and Research Operations at Ribometrix. He has 30 years of experience in innovative drug discovery and is a leader in the field of lead generation with experience in academia, start-ups and large pharmaceutical ventures. Previously, he held positions as Executive Director of Lead Generation at Epizyme, Director of Assay Development and Compound Profiling at the UNC Center for Integrative Chemical Biology and Drug Discovery, President and Chief Operating Officer of Amphora Discovery, and Director of Lead Generation Technologies at Eli Lilly and Company. Bill was one of the founders of the Society for Biomolecular Screening (SBS) and served as president from 1998 to 2000. He has served on the board of directors of both SBS and Society for Laboratory Automation and Screening. Bill has worked on over 500 drug discover projects in his career including numerous projects that have entered clinical trials.

Brian Strahl, PhD

Scientific Advisor

Dr. Strahl is a Professor in the Department of Biochemistry & Biophysics at the University of North Carolina at Chapel Hill, where he has been an investigator for the past 10 years. He performed his post-doctoral studies with Dr. C. David Allis at the University of Virginia, where he formally proposed the histone code hypothesis – a far-reaching idea to explain the function of histone modifications. Dr. Strahl has been the recipient of various prestigious awards for his work on histone modifications. He was the recipient of a Presidential Early Career Award for Scientists and Engineers in 2003. Dr. Strahl also received the ASBMB/Schering-Plough Research Institute Award in 2005, and the EUREKA award from the NIH in 2007.

Ian Davis, MD, PhD

Scientific Advisor

Dr. Davis is an Associate Professor in the Department of Genetics & Pediatrics at the University of North Carolina and studies the application of integrated genome-wide approaches to identify the epigenetic and chromatin biology consequences of genetic alterations in human cancers. Following completion of his M.D. from Northwestern University Medical School, Dr. Davis served as a resident and then chief resident in pediatrics at Boston Children’s Hospital. He then completed subspecialty training in pediatric hematology/oncology at Dana-Farber Cancer Institute and Boston Children’s Hospital, during which time he did postdoctoral studies with David Fisher. Dr. Davis holds the G. Denman Hammond Associate Professorship for Childhood Cancer at UNC. His is a Rita Allen Foundation Scholar and has received a Martin D. Abelo Scholar Award from the V Foundation for Cancer Research.

Patrick Hurban, PhD

Scientific Advisor

Dr. Hurban is the Senior Director and Global Head of Translational Genomics at Q2 Solutions, where he is responsible for the identification and implementation of new genomic capabilities, encompassing bioinformatics and wet-laboratory methods, as well as the development and validation of genomic assays to support research and clinical programs. He has over 25 years of experience in molecular genetics, including over 18 years in positions of increasing responsibility in high-profile genomics-focused organizations. His research interests have focused on the genetic control of gene expression and have spanned diverse fields such as toxicology, developmental, and cancer biology. Dr. Hurban earned his PhD in Human Genetics from the University of Utah before serving as a postdoctoral research fellow of the American Cancer Society in the Department of Developmental Biology at Stanford University.

Want to join the team?

We’re looking for ambitious, enthusiastic scientists and business people to join our team. If this sounds like you, send us your resume and tell us what you can bring to our company that sets you apart from anyone else.